Citius Oncology, Inc. (CTOR) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Citius Oncology, Inc. (CTOR) Earnings Overview
As of June 29, 2026, Citius Oncology, Inc. (CTOR) reported trailing twelve-month net income of -$43M, reflecting -13.3% year-over-year growth. The company earned $-0.42 per diluted share over the past four quarters.
Looking at the long-term picture, CTOR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2022.
Citius Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($349M net income, 22.7% margin), NKTR (-$158M net income, -297.1% margin), ADMA ($165M net income, 28.8% margin), CTOR has comparable earnings metrics. Compare CTOR vs HALO →
CTOR Earnings vs Peers
Earnings metrics vs comparable public companies
CTOR Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$25M | -17.1% | -$24M | $-0.34 | - | - |
| 2024 | -$21M | -66.6% | -$21M | $-0.30 | - | - |
| 2023 | -$13M | -16.9% | -$12M | $-0.19 | - | - |
| 2022 | -$11M | - | -$10M | $-0.08 | - | - |
Download Data
Export CTOR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CTOR — Frequently Asked Questions
Quick answers to the most common questions about buying CTOR stock.
What is CTOR earnings per share (EPS)?
CTOR trailing twelve-month (TTM) diluted EPS is $-0.42, reflecting -13.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Citius Oncology, Inc.'s net income?
Citius Oncology, Inc. (CTOR) trailing twelve-month net income is $-43M as of 2025. Earnings declined -13.3% year-over-year.
Is CTOR profitable?
CTOR is not currently profitable on a TTM basis, reporting a net loss of $-43M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CTOR's earnings growth rate?
CTOR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are CTOR's profit margins?
Citius Oncology, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -54.4%.
Is CTOR growing earnings?
CTOR earnings are declining — EPS fell -13.3% year-over-year. TTM net income dropped to $-43M. This contrasts with the 5-year CAGR of N/A.
What was CTOR's best earnings year?
Citius Oncology, Inc.'s highest annual net income on record is $-11M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were CTOR's earnings last quarter?
CTOR's most recent reported quarter was Q2 2026. Net income was $-27M with diluted EPS of $-0.27. For a full breakdown of all quarters, see the quarterly earnings table on this page.